Cuorips Stock (4894): Price, Board Talking Points and Outlook

Cuorips Inc. (TSE: 4894) is an iPS-cell regenerative-medicine company listed on the Tokyo Stock Exchange Growth market, developing "Reheart," a cardiomyocyte sheet derived from iPS cells. On March 6, 2026 it received conditional, time-limited manufacturing and marketing approval from Japan's Ministry of Health, Labour and Welfare — yet the stock had already peaked at ¥12,400 on February 19, before the approval, and fell to ¥3,610 by June 11. Japanese retail boards keep circling the same question: why did the stock collapse after the approval it had waited years for? This page summarizes the board talking points as of July 2026, the state of the business, and how to read the stock.

▶ Browse the futures markets on WEEX ・ Yahoo Finance Japan board (4894)

Board and community talking points

Discussion around Cuorips concentrates almost entirely on the approval timeline and what came after. The recurring themes observed as of July 2026:

• A textbook "sell the news." The run-up began on February 13, 2026, when the company disclosed that its application was on the agenda of the health ministry's expert committee; the stock went limit-up on February 16 and peaked at ¥12,400 on February 19, the day a review-status disclosure landed. When the actual approval arrived on March 6, the bounce lasted only days, and the shares slid to a year-to-date low of ¥3,610 by June 11 — roughly 71% below the February peak.
• Approval is not revenue. The March decision is Japan's conditional, time-limited approval track for regenerative-medicine products, not full approval. The company says it will promptly apply for insurance-price listing, plans a domestic launch around autumn 2026, and must complete an all-case post-marketing survey targeting 75 patients. Approval date, launch date and full-approval date are three different things — and the gaps between them are exactly where bulls and bears diverge.
• Widening losses on a strong balance sheet. FY2026/3 brought sales of ¥210 million against a net loss of ¥1.02 billion, and the company guides to a ¥1.39 billion net loss for FY2027/3 as research spending rises roughly 90%. The counterweight: an equity ratio of 91.6% and no supervisory or delisting designation of any kind as of July 2026. Retail sentiment on Minkabu still leans bullish.

The business and what to watch

Cuorips listed in 2023 and focuses on commercializing iPS-cell-derived cardiomyocyte sheets. Market capitalization is about ¥36.4 billion; the company pays no dividend and, being loss-making, shows no P/E. Its board includes Yoshiki Sawa, the cardiac surgeon who pioneered the iPS heart-sheet field; a July 14, 2026 disclosure noted his attendance at a government drug-discovery council.

The central asset is Reheart's conditional approval, granted on March 6, 2026 for severe heart failure caused by ischemic cardiomyopathy in patients who respond inadequately to standard therapies, including drugs and invasive treatment. The company targets a domestic launch around autumn 2026 once insurance-price listing is secured, and says overseas expansion will accelerate. What to watch from here: the insurance-listing timetable, first-quarter results due August 13, 2026, and progress on the 75-case post-marketing survey.

How to read the stock

From a 2023 close of ¥2,321 the stock reached ¥10,050 in 2024 before closing that year at ¥4,610, then swung between ¥9,710 and ¥4,300 in 2025 to close at ¥6,030. In 2026 it opened at ¥6,070, spiked to ¥12,400 on February 19 on approval anticipation, then fell to ¥3,610 by June 11; it traded around ¥4,400 as of July 17. Bulls argue the hardest gate — approval — has been passed, the autumn 2026 launch is approaching, and the 91.6% equity ratio removes near-term financing fear. Bears counter that meaningful revenue is still ahead, losses are widening, and the post-approval slide shows how much was already priced in; full approval still requires the 75-case survey. These are observed views, not our recommendation, and this page sets no price target.

Trading global markets on WEEX

To own Cuorips shares themselves, the standard route is an account with a Japanese brokerage. WEEX does not list the Japanese equity or any tokenized version of it. What WEEX offers is global-market access of a different kind: major crypto assets such as Bitcoin — tradable as futures (long or short, with leverage) as well as spot — plus index-tracking tokens in the QQQON/IVVON class that follow US equity indexes. Tokenized index products are not shares; they are tracking instruments that follow the price of the underlying. See the WEEX futures markets and the how to buy Bitcoin guide.

FAQ

Where can I read the Cuorips message board?

On the Yahoo Finance Japan board (4894) and Minkabu (4894), where retail investors discuss the stock and price.

Why is Cuorips so discussed?

Its iPS heart-cell sheet won conditional approval in March 2026, yet the stock fell hard from a pre-approval peak of ¥12,400 — a sell-the-news arc that keeps the debate alive.

When will Reheart go on sale?

The company plans a domestic launch around autumn 2026, after insurance-price listing; a 75-case all-patient post-marketing survey continues beyond approval.

Does Cuorips pay a dividend?

No. As of July 2026 it pays no dividend and forecasts another net loss for FY2027/3.

When are the next results?

First-quarter FY2027/3 results are scheduled for August 13, 2026.

This article is for information only and is not investment advice; nothing here is a recommendation to buy or sell.

Related coverage

• Oriental Land (4661): price, board talking points and outlook
• Kawasaki Kisen (K Line) (9107): price, board talking points and outlook
• NTT (9432): price, board talking points and outlook